AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries

AbbVie has had success with its new pan-genotypic hepatitis C drug Mavyret, generating blockbuster-level sales at the expense of competitors. Now, the company has inked a deal with the Medicines Patent Pool to boost access to the drug in nearly 100 low- and middle-income countries and territories.